Icoria Awarded $1.2 Million Liver Injury Contract from NIEHS

31-Aug-2005

Icoria, Inc. announced that it has received a $1.2 million Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Environmental Health Sciences, National Institutes of Health to discover biomarkers for drug-induced liver injury. This research could lead to the development of new diagnostics for identifying hepatotoxicity and the progression of liver disease.

Icoria is currently developing multi-analyte biomarker panels to diagnose drug-induced hepatotoxicity, non-alcoholic fatty liver disease and other liver problems where present diagnostics approaches may be limited in sensitivity and accuracy. The contract will support Icoria's continued research into proprietary serum and urine biomarkers that can measure liver health and predict the severity of liver pathology.

The SBIR Phase II contract is worth up to $1,213,492 over a two-year period. This project is funded with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services. Icoria estimates that the Federal funds allocated under these contracts will entirely support its "Metabolomics and Pathway Linkage: Urine, Serum, and liver" research program.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures